---
document_datetime: 2023-10-31 11:05:58
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pemazyre-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: pemazyre-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.8741654
conversion_datetime: 2025-12-25 01:47:06.488134
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Pemazyre

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                    |
|----------------------|-----------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10923 /202210  | Periodic Safety Update EU Single assessment - pemigatinib                                           | 25/05/2023                          | 26/07/2023                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10923/202210. |
| IA/0011              | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the | 24/03/2023                          | n/a                                         |                                  |                                                                                                                                            |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10923 /202204 | Periodic Safety Update EU Single assessment - pemigatinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 15/12/2022 | 24/02/2023 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10923/202204.                                                                                                                                                                                                                                                                                                                                         |
| R/0007              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 15/12/2022 | 23/02/2023 |             | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Pemazyre, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| IB/0009/G           | This was an application for a group of variations. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished | 02/12/2022 | 23/02/2023 | SmPC        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0008/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor | 01/12/2022 | n/a |

<div style=\"page-break-after: always\"></div>

| PSUSA/10923 /202110   | Periodic Safety Update EU Single assessment - pemigatinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 10/06/2022   | n/a        |                   | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0005               | Update of sections 4.4, 4.8 and 5.1 of the SmPC based on the final results from study INCB054828 (FIGHT-202) listed as a specific obligation in the Annex II (SOB/002); this is a phase 2 study investigating the efficacy and safety of pemigatinib in adults with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 translocations who failed previous therapy. The Annex II has been updated accordingly. RMP version 2.0 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 19/05/2022   | 23/02/2023 | SmPC and Annex II | The main proposed changes in the SmPC are as follows: - Section 4.4: update of data on Hyperphosphatemia and Hypophosphatemia based on INCB 54828-202 final CSR - Section 4.8: update of frequency of AEs and description of Hyperphosphatemia and Serious retinal detachment based on INCB 54828-202 final CSR - Section 5.1: update of efficacy results based on INCB 54828-202 final CSR For more information, please refer to the Summary of Product Characteristics.          |
| R/0003                | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 16/12/2021   | 16/02/2022 | SmPC and PL       | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Pemazyre, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| PSUSA/10923 /202104   | Periodic Safety Update EU Single assessment - pemigatinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 02/12/2021   | n/a        |                   | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| IB/0001   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)   | 03/08/2021   | 16/02/2022   | SmPC   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------|